Patients with EGFR-positive NSCLC characterized by a confirmed BIM deletion polymorphism also have a shorter PFS (Isobe et al., 2014; Lee et al., 2014; Zhao et al., 2014). This evidence concerns the gene EGFR and non-small cell lung carcinoma.